Michael Ulz
Stock Analyst at Baird
(4.15)
# 501
Out of 4,981 analysts
100
Total ratings
50%
Success rate
16.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $42 → $25 | $6.29 | +297.46% | 7 | Aug 12, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $312 → $405 | $461.14 | -12.17% | 11 | Aug 1, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $55 → $62 | $61.10 | +1.47% | 5 | Jul 31, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $4.57 | +447.65% | 12 | May 9, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $105 → $102 | $24.09 | +323.50% | 3 | Apr 24, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $3.91 | +411.51% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $1.91 | +1,051.83% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $9.95 | +191.46% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $8.61 | -18.70% | 7 | Mar 5, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $2.27 | +781.06% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $0.98 | +918.33% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $42.85 | +124.04% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $12.86 | +304.35% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $74.19 | -23.17% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $28.67 | -5.82% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $0.96 | +632.37% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $10.71 | +152.10% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $1.36 | +1,370.59% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.22 | +1,297.52% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.75 | +1,230.32% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $3.02 | -0.66% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $4.79 | +526.30% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $500 | $7.17 | +6,873.50% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $29.00 | +175.86% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $7.73 | +94.05% | 3 | Jul 12, 2017 |
Karyopharm Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $25
Current: $6.29
Upside: +297.46%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $312 → $405
Current: $461.14
Upside: -12.17%
Ionis Pharmaceuticals
Jul 31, 2025
Upgrades: Overweight
Price Target: $55 → $62
Current: $61.10
Upside: +1.47%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $4.57
Upside: +447.65%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105 → $102
Current: $24.09
Upside: +323.50%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $3.91
Upside: +411.51%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $1.91
Upside: +1,051.83%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $9.95
Upside: +191.46%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $8.61
Upside: -18.70%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.27
Upside: +781.06%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $0.98
Upside: +918.33%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $42.85
Upside: +124.04%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $12.86
Upside: +304.35%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $74.19
Upside: -23.17%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $28.67
Upside: -5.82%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $0.96
Upside: +632.37%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $10.71
Upside: +152.10%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $1.36
Upside: +1,370.59%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.22
Upside: +1,297.52%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.75
Upside: +1,230.32%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $3.02
Upside: -0.66%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $4.79
Upside: +526.30%
May 28, 2020
Maintains: Outperform
Price Target: $300 → $500
Current: $7.17
Upside: +6,873.50%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $29.00
Upside: +175.86%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $7.73
Upside: +94.05%